.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BE11_Udenafil.Udenafil

Information

Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor used primarily for the treatment of erectile dysfunction. It exerts its effect by enhancing the nitric oxide–cGMP pathway, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum. Udenafil is approved for use in several countries, but is not approved by the FDA in the United States.

Pharmacokinetics

Pharmacokinetic parameters obtained from healthy adult male volunteers following single oral administration.

References

1. Choi, HK, et al., & Shin, JG (2016). The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. Journal of clinical pharmacology 56(11) 1372–1377. DOI:10.1002/jcph.739 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27006150

2. Shin, KH, et al., & Yu, KS (2010). Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. British journal of clinical pharmacology 69(3) 307–310. DOI:10.1111/j.1365-2125.2009.03601.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20233203

3. Porst, H, et al., & Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. The journal of sexual medicine 10(1) 130–171. DOI:10.1111/jsm.12023 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23343170

Revisions

• 06/2025 initial generated model